Company: ALX Oncology
Job title: Chief Scientific Officer
Dr. Hong Wan is currently Chief Scientific Officer at ALX Oncology, a clinical-stage immune-oncology company. Dr. Wan previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Dr. Wan held previous leadership roles in Clinical Translational Medicine and Discovery Research at Pfizer, Wyeth Research, and Renovis. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.
Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity 9:30 am
• Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types • Review preclinical studies where ALX148 bridges innate and…Read more
day: Day One